
https://www.science.org/content/blog-post/targeting-proteins-destruction
# Targeting Proteins for Destruction (May 2015)

## 1. SUMMARY
This 2015 commentary discusses a breakthrough paper by Jay Bradner's group at Harvard/Dana-Farber demonstrating a new method for targeted protein degradation. The approach leverages thalidomide's mechanism - specifically how its pthalimide component binds to cereblon (CRBN), part of a ubiquitin ligase complex. By conjugating this pthalimide group to known protein-binding ligands (like JQ1 for BRD4), the researchers could redirect the cell's natural protein degradation machinery to eliminate specific target proteins.

The technique showed striking effectiveness: BRD4 was completely eliminated within two hours of treatment, with high specificity (only affecting other bromodomain subtypes as expected). The system achieved stronger downstream effects than traditional inhibition. The article compares this approach to PROTAC (Proteolysis Targeting Chimeras) technology, noting similar objectives but a potentially simpler chemical scaffold.

Key challenges identified include the need for good ligands with appropriate attachment points, ensuring cell penetration of the hybrid molecules, managing potential teratogenicity risks, and addressing pharmacokinetics for therapeutic applications. The authors raise questions about the feasibility of targeting "intractable" proteins that lack known small-molecule ligands, which they describe as the most speculative aspect of the work.

## 2. HISTORY
The 2015 discovery reported in this article catalyzed the emergence of **targeted protein degradation (TPD)** as a major therapeutic modality over subsequent years, with profound real-world impact:

**Clinical translation and FDA approvals**: Multiple protein degrader drugs have entered clinical trials, with **lenalidomide and pomalidomide** (both IMiDs) already approved by 2015 for multiple myeloma and other cancers. These drugs work through the exact cereblon mechanism described in the article. Since then, **novel cereblon-based degraders** have progressed through clinical development targeting different proteins. The first-in-class **PROTAC drug ARV-471** (Arvinas, targeting estrogen receptor for breast cancer) entered clinical trials around 2019-2020 and showed promising Phase 2 results, demonstrating proof-of-concept for small-molecule degraders as drugs.

**Technology development and adoption**: The field expanded dramatically. **Arvinas** (founded by PROTAC pioneer Craig Crews, mentioned in the article) became a public company (NASDAQ: ARVN) and advanced multiple PROTAC programs into clinical trials targeting ER, AR, and other proteins. **Kymera Therapeutics** (founded 2016) developed IRAK4, STAT3, and other degraders. **C4 Therapeutics** (founded 2015, founded by Jay Bradner himself) focused on cereblon-based degraders. **Novartis, GSK, Pfizer, Merck, Roche** established major TPD collaborations and internal programs, validating the therapeutic potential.

**Commercial landscape**: By 2020-2023, TPD companies raised **hundreds of millions in funding**. The article's mention of GSK working on PROTACs proved prescient - GSK entered multiple partnerships and advanced degraders. The regulatory precedent from IMiD drugs provided a crucial pathway for informing safety evaluation of new degraders.

**Scientific impact**: Target proteins successfully degraded expanded from BRD4 and FKBP to include **kinases, nuclear receptors, transcription factors, and previously "undruggable" targets** like mutant KRAS and MYC through protein-protein interaction disruptors converted to degraders. Academic chemistry and structural biology efforts systematically mapped cereblon recruitment, linker chemistry, and degrader design rules.

The article's skepticism about targeting proteins without ligands was partially addressed by subsequent developments including **fragment-based approaches**, **computational screening** coupled with cell-based validation readouts, and evolving the molecular glues concept. However, finding suitable ligands remains a core challenge.

## 3. PREDICTIONS

**Prediction: "The impressive effects of this system 'prompts consideration of therapeutic development'"**
- **Outcome**: Highly successful. Multiple protein degrader programs entered clinical trials within 3-5 years, demonstrating therapeutic development was indeed viable. ARV-471 and other clinical candidates proved the approach works in humans.
- **Bigger picture**: The drug class validated as therapeutically relevant, with clinical data on proof-of-concept and tolerability.

**Prediction: "Anything targeting CRBN would be expected to be at risk of being teratogenic... PK of the resulting molecular hybrid to work out"**
- **Outcome**: Partial. Teratogenicity concerns proved manageable through indication selection and clinical safety testing. IMiD drugs provided extensive safety data and precedent. PK challenges varied by molecule but were generally solvable.
- **Bigger picture**: Safety profile has been generally acceptable in clinical trials, similar to traditional small molecules.

**Prediction: Specificity concerns about "nuking a protein from orbit... careful about where you're dropping the bomb"**
- **Outcome**: Mixed. Most degrader programs showed high specificity in preclinical testing. However, unexpected on-target toxicity and off-target effects emerged in some clinical contexts. The selectivity was generally better than predicted.
- **Bigger picture**: The ubiquitin ligase system's natural specificity helps prevent widespread off-target degradation.

**Prediction (skepticism): Difficulty targeting "intractable" proteins like p53 without known ligands**
- **Outcome**: Mostly correct. Proteins without ligandable sites remain challenging. However, the field successfully targeted some previously undruggable proteins through creative approaches and natural product-inspired molecular glues.
- **Bigger picture**: Target scope expanded significantly but practical limits clearly exist.

**Prediction: GSK's PROTAC collaboration relevance**
- **Outcome**: Confirmed. GSK continued investing in TPD through multiple partnerships and internal programs across the late 2010s and early 2020s.

**Overall prediction accuracy**: The article was **cautiously optimistic and highly prescient**. It correctly identified therapeutic development as the key direction and raised valid concerns about practical challenges, most of which were subsequently addressed through scientific progress and clinical validation. It underestimated the speed and scale of industrial adoption (companies like Arvinas, Kymera, C4 becoming major players within 5 years). The skepticism about "intractable targets" represented appropriate scientific discipline rather than lack of vision.  

## 4. INTEREST
**Rating: 9/10**

This 2015 article captured the emergence of a genuinely transformative therapeutic modality at its dawn. The cereblon-based degradation concept has since become a pillar of drug discovery. The commentary correctly predicted the key challenges and the therapeutic potential. While there are more influential papers in absolute terms, this represents the rare case where a "hot paper" commentary actually understated the long-term impact.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20150526-targeting-proteins-destruction.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_